Page last updated: 2024-12-05

2,3,7,8-tetrachlorodibenzodioxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3,7,8-Tetrachlorodibenzodioxin (2,3,7,8-TCDD) is a highly toxic and persistent environmental contaminant. It is a member of the dioxin family, which are a group of chlorinated aromatic compounds. 2,3,7,8-TCDD is formed as an unintended byproduct of various industrial processes, including the production of herbicides, pesticides, and paper pulp bleaching. 2,3,7,8-TCDD is known to be a potent carcinogen, teratogen, and mutagen. It can accumulate in the food chain and is a major environmental concern due to its toxicity and persistence in the environment. Extensive research has focused on understanding the mechanisms of 2,3,7,8-TCDD toxicity, its environmental fate, and its potential for bioremediation. Studies on 2,3,7,8-TCDD are important for developing strategies to prevent its formation, mitigate its environmental impact, and protect human health.'

Tetrachlorodibenzodioxin: A mixture of isomers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15625
CHEMBL ID30327
CHEBI ID28119
SCHEMBL ID8939

Synonyms (59)

Synonym
tetradioxin
2,3,7,8-tetrachlorodibenzodioxine
CHEBI:28119 ,
dioxin
dioxine
2,3,7,8-tetrachlorooxanthrene
2,3,7,8-tcdd
2,3,7,8-tetrachloro-dibenzo[b,e][1,4]dioxin
dibenzo-p-dioxin, 2,3,7,8-tetrachloro-
[3h]-tcdd
bdbm23927
2,3,7,8-tetrachlorodibenzo(b,e)(1,4)dioxin
hsdb 4151
ccris 576
tcdbd
2,3,7,8-tetrachlorodibenzo-1,4-dioxin
dibenzo(b,e)(1,4)dioxin, 2,3,7,8-tetrachloro-
einecs 217-122-7
brn 0271116
dioxin (herbicide contaminant)
2,3,7,8-czterochlorodwubenzo-p-dwuoksyny [polish]
dioksyny [polish]
nci-c03714
C07557
tcdd
pcdd 48
2,3,7,8-tetrachlorodibenzo-p-dioxin
2,3,7,8-tetrachlorodibenzodioxin
1746-01-6
tetrachlorodibenzodioxin
2,3,7,8-tetrachloro-dibenzo[1,4]dioxine
CHEMBL30327
c-132,3,7,8-tcdd
dioksyny
do80m48b6o ,
2,3,7,8-czterochlorodwubenzo-p-dwuoksyny
unii-do80m48b6o
NCGC00260338-01
cas-1746-01-6
dtxsid2021315 ,
tox21_202792
dtxcid001315
2,3,7,8-tetrachloro-p-dioxin
BRD-K90697689-001-01-5
AKOS022181518
SCHEMBL8939
tetrachlorodibenzo-p-dioxin, 2,3,7,8-
2,3,7,8-tetrachlorodibenzo-p-dioxin [hsdb]
tcdd [mi]
2,3,7,8-tetrachlorodibenzo(b,e)(1,4)dioxan
dibenzo[b,e][1,4]dioxin, 2,3,7,8-tetrachloro-
2,3,7,8-tetrachlorooxanthrene #
gtpl9642
2,3,7,8-tetrachlorodibenzo[b,e][1,4]dioxine
2,3,7,8-tetrachlorodibenzo-p-dioxin 10 microg/ml in toluene
Q52822
nsc767477
nsc-767477
2,3,7,8-tetrachlorodibenzo[1,4]dioxin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polychlorinated dibenzodioxineAny dibenzodioxine in which two or more hydrogens have been replaced by chlorines.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (13)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Regulation of lipid metabolism by PPARalpha1001
PPARA activates gene expression1001
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Xenobiotics450
Aryl hydrocarbon receptor signalling51
Ahr Signal Transduction Pathway31
Aryl hydrocarbon receptor01
Aryl hydrocarbon receptor pathway11

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.01010.001022.650876.6163AID1224838; AID1224839; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.00190.001530.607315,848.9004AID1224841; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency0.21320.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.00270.000229.305416,493.5996AID1259244; AID1259248; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency0.00090.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00110.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.00030.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.00600.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.00600.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vascular endothelial growth factor receptor 1 Homo sapiens (human)IC50 (µMol)0.00270.00010.29147.0000AID625231
Vascular endothelial growth factor receptor 1 Homo sapiens (human)Ki0.00070.00070.02090.0600AID625231
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Rattus norvegicus (Norway rat)EC50 (µMol)0.01000.00152.205710.0000AID39064
Aryl hydrocarbon receptorMus musculus (house mouse)EC50 (µMol)0.00000.00000.00000.0000AID631103
Aryl hydrocarbon receptorHomo sapiens (human)EC50 (µMol)0.01000.00151.976910.0000AID39064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel developmentAryl hydrocarbon receptorHomo sapiens (human)
regulation of adaptive immune responseAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of T cell mediated immune response to tumor cellAryl hydrocarbon receptorHomo sapiens (human)
regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
xenobiotic metabolic processAryl hydrocarbon receptorHomo sapiens (human)
apoptotic processAryl hydrocarbon receptorHomo sapiens (human)
response to xenobiotic stimulusAryl hydrocarbon receptorHomo sapiens (human)
response to toxic substanceAryl hydrocarbon receptorHomo sapiens (human)
regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
cAMP-mediated signalingAryl hydrocarbon receptorHomo sapiens (human)
intracellular receptor signaling pathwayAryl hydrocarbon receptorHomo sapiens (human)
regulation of B cell proliferationAryl hydrocarbon receptorHomo sapiens (human)
circadian regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of inflammatory responseAryl hydrocarbon receptorHomo sapiens (human)
cellular response to molecule of bacterial originAryl hydrocarbon receptorHomo sapiens (human)
cellular response to cAMPAryl hydrocarbon receptorHomo sapiens (human)
cellular response to forskolinAryl hydrocarbon receptorHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxineAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
transcription cis-regulatory region bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAryl hydrocarbon receptorHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
TFIID-class transcription factor complex bindingAryl hydrocarbon receptorHomo sapiens (human)
transcription coactivator bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activityAryl hydrocarbon receptorHomo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
protein bindingAryl hydrocarbon receptorHomo sapiens (human)
TBP-class protein bindingAryl hydrocarbon receptorHomo sapiens (human)
protein homodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
protein heterodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
Hsp90 protein bindingAryl hydrocarbon receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAryl hydrocarbon receptorHomo sapiens (human)
E-box bindingAryl hydrocarbon receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nuclear aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytosolAryl hydrocarbon receptorHomo sapiens (human)
chromatinAryl hydrocarbon receptorHomo sapiens (human)
transcription regulator complexAryl hydrocarbon receptorHomo sapiens (human)
protein-containing complexAryl hydrocarbon receptorHomo sapiens (human)
cytosolic aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID196196Serum T4 level was determined in TCDD-treated rat at a dose of 50 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID196193Serum T4 level was determined in TCDD-treated rat at a dose of 12 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID1487309Agonist activity at AhR in human HepG2 cells at 5 to 20 nM after 42 hrs in presence of AhR antagonist GNF-351 by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Gerontoxanthone B from Maclura cochinchinensis var. gerontogea exhibits anti-inflammatory potential as an aryl hydrocarbon receptor agonist.
AID197228Liver weight was determined in rats1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID196197Serum T4 level was determined in rats1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID1310891Agonist activity at AHR expressed in human HepG2 cells after 24 hrs by pXRE-luciferase reporter gene assay2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.
AID169708Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 12 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID1487310Agonist activity at AhR in human HepG2 cells at 5 to 20 nM after 42 hrs in presence of AhR antagonist 3',4'-DMF by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Gerontoxanthone B from Maclura cochinchinensis var. gerontogea exhibits anti-inflammatory potential as an aryl hydrocarbon receptor agonist.
AID1182268Half life in human2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Synthesis and biological evaluation of 2,3'-diindolylmethanes as agonists of aryl hydrocarbon receptor.
AID196195Serum T4 level was determined in TCDD-treated rat at a dose of 37 ug/kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID39092Compound tested for its binding to human Orphan receptor (AhR); Active2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
An electrochemical device for the assay of the interaction between a dioxin receptor and its various ligands.
AID197221Body weight was determined in TCDD-treated rats at a dose of 25 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID169707Number of T4 binding sites in rat liver from TCDD treated rats1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197223Body weight was determined in TCDD-treated rats at a dose of 50 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID169710Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 37 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID682136TP_TRANSPORTER: Western in vivo SD rat, liver2002The Journal of pharmacology and experimental therapeutics, Jan, Volume: 300, Issue:1
Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways.
AID1487314Agonist activity at AhR in human HuH7 cells assessed as reduction in IL-1beta induced increase in SAA1 mRNA level at 10 nM pretreated for 20 hrs followed by Il-1beta addition measured after 4 hrs by qRT-PCR analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Gerontoxanthone B from Maclura cochinchinensis var. gerontogea exhibits anti-inflammatory potential as an aryl hydrocarbon receptor agonist.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID210547Binding affinity of [125I]T4 to rat liver nuclear extract (CONTROL)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197219Body weight (after treatment) was determined1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197222Body weight was determined in TCDD-treated rats at a dose of 37 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1897744Inhibition of Hedgehog-signalling dependent purmorphamine induced osteoblast differentiation in mouse C3H 10T1/2 cells assessed as reduction in ALP expression at 0.01 to 100 uM incubated for 96 hrs by CDP-Star luminogenic substrate based assay2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
The Highly Potent AhR Agonist Picoberin Modulates Hh-Dependent Osteoblast Differentiation.
AID1141941Agonist activity at AHR in FVB/N mouse primary mammary epithelial cells assessed as upregulation of desmoglein-3 protein level at 10 nM after 144 hrs by Western blot analysis in presence of FGF22014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor.
AID169709Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 25 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID210548Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 12 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197220Body weight was determined in TCDD-treated rat at a dose of 12 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID431863Induction of mouse AhR LBD transcriptional activity in mouse hepa1 cells transfected with AhR response element co expressed with XRE after 6 hrs by luciferase reporter gene assay relative to control2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands.
AID197226Liver weight was determined in TCDD-treated rats at a dose of 37 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID210549Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 25 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID39064Affinity on cytosolic Aromatic hydrocarbon receptor (Ah)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID196194Serum T4 level was determined in TCDD-treated rat at a dose of 25 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID210550Binding affinity of [125I]-T4 to rat liver nuclear extract at a dose of 37 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID631103Agonist activity at Ah receptor in genetically engineered mouse cells expressing firefly luciferase gene by CALUX transactivational assay2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
AID169711Number of T4 binding sites in rat liver from TCDD treated rats at a dose of 50 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197227Liver weight was determined in TCDD-treated rats at a dose of 50 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID210551Binding affinity of [125I]T4 to rat liver nuclear extract at a dose of 50 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID197224Liver weight was determined in TCDD-treated rat at a dose of 12 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
AID678816TP_TRANSPORTER: Northern blot in vivo Fischer male rat1988Journal of the National Cancer Institute, Nov-02, Volume: 80, Issue:17
Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics.
AID467952Induction of CYP1B1 expression in human MCF7 cells at 10 nM after 24 hrs by 7-ethoxyresorufin-O-deethelase assay2009Journal of natural products, Aug, Volume: 72, Issue:8
The methoxylated flavones eupatorin and cirsiliol induce CYP1 enzyme expression in MCF7 cells.
AID197225Liver weight was determined in TCDD-treated rats at a dose of 25 ug/Kg1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Polychlorinated biphenyls and related compound interactions with specific binding sites for thyroxine in rat liver nuclear extracts.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's1 (6.67)18.2507
2000's5 (33.33)29.6817
2010's6 (40.00)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]